Xeris Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Xeris Pharmaceuticals Inc. (XERS) Reports In-Line Q1 EPS, Revenues Beat
May 7, 2020 7:48 AM EDTXeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q1 EPS of ($0.89), in-line with the analyst estimate of ($0.89). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.43 million.
Starting in January with the field launch, Gvoke PFS began to see a very... More
